 Mothership | Mothership operates in Logistics & Supply Chain. | |
 Motif Analytics | Motif Analytics operates in Data & Analytics. | |
 Motif Neurotech | Private therapeutic neurotechnology company founded by Jacob Robinson, Sameer Sheth and Sunil Sheth. Develops investigational XCS/DOT microstimulation technology for treatment-resistant depression; 2026 IDE permits a clinical study, not marketing. | Houston, Texas · Houston, Texas, United States |
 Motion | Motion operates in Robotics & Automation. | |
 Motley | Company operating in AI. | |
 MOTOR Ai | Berlin autonomous-driving software company developing a Level 4 driving stack for public transport and other mobility applications. Its architecture uses cognitive neuroscience and active inference to support explainable decisions, combined with automotive safety engineering and vehicle integration. | |
 Motorica | Motorica operates in Gaming. | |
 Motorway | Company operating in Mobility & Transportation. | |
 Mottu | | |
 Movable Ink | Marketing & Advertising company. | |
 Movandi | Movandi operates in Telecom. | |
 Move Loot | E-Commerce & Marketplace company. | |
 MoveInSync | MoveInSync operates in Mobility & Transportation. | |
 Movement | Company operating in Developer Tools. | |
 Moveworks | Company operating in AI. | |
 Moveworks | | |
 Movidius | Movidius operates in Hardware & Semiconductors. | |
 Movieclips | | |
 Mowito | | |
 Mozart | Mozart operates in Media & Entertainment. | |
 Mozart AI | Mozart AI operates in Media & Entertainment. | |
 Mozart Therapeutics | | |
 Mozper | | |
 mParticle | Data & Analytics company. | |
 mPharma | Company operating in Healthcare. | |
 Mpiriq | Company operating in Healthcare. | |
 MPL | Company operating in Gaming. | |
 mPrest | | |
 mQube | Company operating in AI. | |
 MRIguidance | MRIguidance is the Utrecht medical-imaging company legally identified as MRIguidance B.V. in FDA filings. MR physicist Peter Seevinck, image scientist Marijn van Stralen and entrepreneur Roel Raatgever founded it in 2016 as a University Medical Center Utrecht spinout. BoneMRI is its product and trademark, rather than a separately inferred company rename or acquisition.
BoneMRI combines dedicated MRI acquisition and deep learning to generate three-dimensional CT-like bone images alongside aligned soft-tissue imaging. It supports radiology, musculoskeletal diagnostics and spine surgical planning and navigation without adding ionizing-radiation imaging. The software integrates with DICOM/PACS workflows through hospital or cloud processing. FDA record K233030 confirms a substantially-equivalent 510(k) clearance on 1 March 2024; scanner, anatomy and software-version indications apply. The February 2026 release describes spinal stitching, expanded scanner compatibility and IT improvements. Clinical superiority and market-leading statements remain attributed to the issuer.
The current public directory names 20 management/staff members and three advisers. Guido Zijl succeeded Roel Kellenaers as CEO in February 2026; Seevinck is CSO and van Stralen CTO. Founder Raatgever died in late 2021, and the intervening leadership roles are recorded historically. Verified financing consists of a EUR1.5 million seed announced on 16 October 2018, a EUR750,000 bridge announced on 9 July 2020 involving an EIT Health co-investment grant in return for options and existing shareholders and a USD1.25 million Mammoth Scientific investment announced on 25 August 2021 through Mammoth Private Capital. EIT Health Bridgehead Global support in 2021 included a separate grant whose recipient-specific cash amount is undisclosed. Hospital customers, distribution partners, university collaborators and personal scientific grants are distinguished from company equity investments. A company-named NWO Take-off phase 2 development award dated 23 June 2017 is separately recorded with amount and instrument undisclosed; an award does not establish cash drawdown. | Utrecht, Netherlands · New York, United States |
 MrJeff | MrJeff operates in Consumer. | |
 MSP Corp | MSP Corp is a Canadian managed IT services provider that operates a national network of regional service teams and acquires independent managed service providers. It remotely manages IT infrastructure, cloud environments and cybersecurity for small and midsize businesses, with services including end-user support, monitoring, backup and disaster recovery, data governance and Microsoft cloud integration. Its managed AI services help organizations deploy Microsoft Copilot, build secure AI agents and retrieval-based systems, automate workflows, and manage AI governance, adoption and operating costs. The current group combines the MSP Corp platform and Groupe Access following their 2023 merger. Niobrara Capital announced its acquisition of the business in September 2026 for undisclosed terms. | |
 MSP Growth Hacks | Publishes research, articles, guides, workshops and books that help managed service providers grow their businesses. Its content covers marketing, sales, financial management and service operations, alongside growth strategy and coaching. Top Down Ventures acquired the publishing platform in May 2025. | |
 MTailor | | |
 Mtor | Operates an automotive spare-parts marketplace in Egypt, serving repair workshops with sourcing and delivery. | |
 Mu Sigma | | |
 MUBI | Company operating in Media & Entertainment. | |
 Mudafy | Latin American real-estate platform. | |
 Mudrex | Company operating in Crypto & Web3. | |
 Mudstack | Company operating in Gaming. | |
 MuleSoft | | |
 MuleSoft, Inc. | | |
 Multi-Specialty HealthCare | An outpatient healthcare provider delivering post-traumatic injury care and physical rehabilitation across the Baltimore-Washington and Delmarva regions. | |
 Multifactor, Inc | Cybersecurity company. | |
 Multiomic Health | Company operating in Biotech & Life Sciences. | |
 Multiplier | AI-native professional-services holding company that acquires tax and accounting firms and embeds in-house AI. Founded in late 2022 by former Stripe APAC executive Noah Pepper. Headquartered in Singapore. | Singapore |
 Multiplier Holdings | Company operating in Enterprise Software. | |
 Multiply | Multiply operates in Fintech. | |
 Multiply Labs | Pharmaceutical robotics. | |
 Multis | Company operating in Fintech. | |
 Multiscale Technologies | Multiscale Technologies, operating as Multiscale AI, develops industrial AI software to optimize semiconductor materials, processes and manufacturing. Its platform combines physics-informed Bayesian digital twins with AI agents that curate fragmented fab data, run virtual experiments, investigate root causes and propose process windows. It integrates a metadata catalog, data curation, active learning, model execution and reusable workflows so engineering teams can adapt analyses across products, process nodes and manufacturing conditions. Natural-language interfaces let engineers request analyses while underlying models incorporate physical simulation, process sequences, measurement data and uncertainty. The company serves semiconductor fabs and manufacturing-material suppliers, with teams in Atlanta, San Francisco and Hyderabad. Micron Ventures publishes Multiscale Technologies as a portfolio investment; the company’s own current site also lists Micron among its investors. | |
 Multitude Insights | Company operating in Enterprise Software. | |
 Multiverse | Multiverse operates in Education. | London, GB |
 Multiverse Labs | | |
 MultiVu | | |
 Muna Therapeutics | Muna Therapeutics develops oral small-molecule medicines intended to preserve brain function in neurodegenerative diseases. Its MiND-MAP discovery platform uses spatial single-cell multi-omics and bioinformatics from human patient tissue to identify mechanisms of resilience to Alzheimer’s, Parkinson’s and other disorders, supported by structural biology and computational chemistry. Lead TREM2 agonist MNA-001 is in Phase 1 testing in healthy young and older adults to modulate microglial function for Alzheimer’s disease; a separate preclinical Kv1.3 blocker program targets neuroinflammation in Parkinson’s and multiple sclerosis. | |
 Munch | Food & Agriculture company. | |
 Mundimoto | Company operating in E-Commerce & Marketplace. | |
 Mundo AI | | |
 Muni | | |
 Munify | | |
 Munily | | |
 Muon | Company operating in Crypto & Web3. | |
 Muon Space | Company operating in Defense & Space. | |
 Mural | Enterprise Software company. | |
 Murphy | Company operating in AI. | |
 Musaic | Musaic developed wireless multiroom hi-fi speakers and music players. Its system combined streaming audio, smartphone control and integrations with connected-home devices. | |
 Mutable | | |
 Mutable Tactics | | |
 Mutiny | Company operating in Marketing & Advertising. | |
 Mutiny | | |
 Muun AI | Muun AI is a Singapore industrial software company that converts existing machine and process telemetry into explainable operational intelligence. Its platform labels sensor signals and production cycles, establishes asset-specific performance baselines, detects drift and anomalies, and produces ranked recommendations with traceable evidence. It works with data exports, historians, databases and live feeds, helping operators reduce excess processing, energy consumption and waste while improving throughput and equipment reliability. Its approach supports human review and introduces prediction or automation only after operational value is demonstrated. | |
 Mux | Mux operates in Enterprise Software. | |
 Muze | | |
 Muzz | | |
 MyBuys | | |
 MyC | SaaS company. | |
 MyCaptain | Provides live online and cohort-based training for careers in marketing, content, business, design and product. Its programs combine practical assignments, mentorship and career support to help students and early-career professionals build job-ready skills. Acquired by Imarticus Learning in May 2025. | |
 MycoWorks | Fungi-based leather materials company. | |
 MyEdSpace | Company operating in Education. | |
 MyEdu | | |
 Myeloid Therapeutics | Myeloid Therapeutics operates in Biotech & Life Sciences. | |
 MyFitnessPal | MyFitnessPal operates in Healthcare. | |
 MyGlamm | MyGlamm operates in Consumer. | |
 MyHeritage | MyHeritage operates in Consumer. | |
 Myia | | |
 Myko AI | | |
 Mylk Guys | | |
 MyMynd | Company operating in HR & Talent. | |
 Mynd | | |
 Mynd Property Management | | |
 MYNTRA | MYNTRA operates in E-Commerce & Marketplace. | |
 MyOme, Inc. | Clinical genetics company. | |
 Myosin Therapeutics | Myosin Therapeutics is a clinical-stage biotechnology company in Jupiter, Florida, developing small molecules that target molecular nanomotor proteins for oncology and central nervous system conditions. Founded in 2020 by Courtney A. Miller, Patrick R. Griffin and Theodore Kamenecka, it is a spinout of the institute now known as the Herbert Wertheim UF Scripps Institute. Its lead oncology program, MT-125, targets non-muscle myosin II and is being evaluated in the Phase 1/2 STAR-GBM trial for newly diagnosed glioblastoma; the company reported first-patient dosing in May 2026. MT-110 is being developed for methamphetamine use disorder. These therapies remain investigational. Founder, Chairperson and CEO Courtney Miller leads eleven publicly listed leadership members and five medical and scientific advisers. The current site lists Griffin and Kamenecka as founders, directors and CSOs. Myosin's first seed financing began in December 2022 and reached $2,999,986 in the March 2023 SEC amendment; its second seed round, announced February 2025, raised over $3 million. DeepWork Capital participated in both, and Mayo Clinic Ventures joined the second. NIH records identify four company grant project series with about $12.083 million in appropriations through fiscal 2026, including ongoing drug-development and clinical research programs. A separate $2 million Florida Cancer Innovation Fund award was announced in March 2026 for the STAR-GBM study. Research grants, clinical designations and conference participation are kept separate from equity financing and drug approval. | |
 MyPetrolPump | | |
 MyRealTrip | MyRealTrip operates in Travel & Hospitality. | |
 Myrobalan Therapeutics | Medford, Massachusetts biotechnology company developing brain-penetrant oral small-molecule therapies intended to address neuroinflammation and promote myelin repair. Founded by Jing Wang, Zhigang He and Guoping Feng, it pursues neurorestorative approaches for multiple sclerosis, ALS, Alzheimer's disease and other CNS conditions. Its investigational programs target CSF1R, GPR17 and TYK2, with biomarker-guided precision neurology supporting development. | |
 Myrodia Therapeutics | Tokyo-based drug-discovery startup developing medicines based on sensory stimulation and the connection between the brain and peripheral organs. Its Sensory Medicine approach uses odor components to transmit signals to brainstem response centers through sensory and vagus nerves, with the aim of inducing protective physiological responses such as metabolic suppression, reduced inflammation and improved organ blood flow. Based on research at Kansai Medical University, the company is developing drug candidates intended to induce an artificial hibernation-like protective state for emergency medical conditions. Its research remains in early nonclinical development. Myrodia combines academic neuroscience with venture-backed drug development and pharmaceutical management expertise. | |
 Mysa | Provides an AI-assisted finance operations platform for businesses. It connects procurement, accounts payable, vendor payments, corporate banking, expense management and accounting workflows, integrating with banks and enterprise resource planning software. Its tools extract invoice data, coordinate approvals, reconcile transactions and maintain audit trails. | |
 Mysten Labs | A web3 infrastructure company that develops the Sui blockchain and supporting tools for decentralized applications. | |
 Mystery.org | | |
 Mythic | Mythic operates in AI. | |
 Mythic AI | Hardware & Semiconductors company. | |
 Mythic Markets | Fractional ownership of collectibles. | |
 Mythic Therapeutics | | |
 MyTime | Company operating in SaaS. | |
 myTomorrows | myTomorrows is an Amsterdam-based health technology company founded by physician Ronald Brus in 2012, with an additional office in New York. Its platform uses AI-supported clinical-trial discovery, treatment matching and patient pre-screening alongside human navigation to connect patients, clinicians, research sites and biopharma companies. It also supports expanded-access programs and real-world data collection. Applications cover serious diseases, including neurological and rare conditions. Michel van Harten leads the company, with Dennis Akkaya overseeing commercial strategy, Vanessa Lemarié operations and Marshall van Beurden technology. Verified funding includes a EUR4.5 million institutional investment in 2014, EUR10 million growth financing in January 2017 and EUR25 million growth equity in November 2025 from Avego Healthcare Capital Fund II. The latter was also announced as USD29 million; both figures describe the same round. The website identifies its publishing legal entity as Impatients N.V. | |
 Mytos | Company operating in Biotech & Life Sciences. | |
 Mytra | Consumer company. | |
 myUpchar | Company operating in Healthcare. | |
 MyVR | | |
 Mznil | | |
 N.Light | | |
 N26 | Fintech company. | |
 N8n | N8n operates in Developer Tools. | |
 NA-KD | Company operating in E-Commerce & Marketplace. | |
 Nabhdrishti Aerospace | Nabhdrishti Aerospace operates in Defense & Space. | |
 Nabis | | |
 Nabla | Company operating in Healthcare. | |
 Nabla Bio | AI protein-design company that engineers antibodies and other biologics. | Boston, Massachusetts |
 Naboo | AI-powered platform that simplifies corporate event planning across the UK and Europe, combining agency service with modern software. Based in Paris; opened a New York office with this round. | Paris, France · New York, New York |
 Naborly | PropTech company. | Toronto, Ontario, CA |
 Nacelle | Company operating in E-Commerce & Marketplace. | |
 Naive | Company operating in AI. | |
 Nakad | Nakad operates in Consumer. | |
 Naked Labs | 3D body scanning home mirror. | |
 NakedPoppy | | |
 Nala | Nala operates in Fintech. | |
 Nalu Medical | Medical-device company founded by Keegan Harper, developing miniature externally powered neurostimulation for peripheral-nerve/spinal pain. Boston Scientific completed its acquisition January 27, 2026. Historical Carlsbad headquarters; post-acquisition executive roles require confirmation. | Carlsbad, California, United States |
 Namecoach | Name pronunciation platform. | Palo Alto, California |
 NameCoach | | |
 Namely | | |
 Namla | Consumer company. | |
 Nango | Developer Tools company. | |
 Nanit | Company operating in Consumer. | |
 NannyML | Company operating in Data & Analytics. | |
 Nano Corp | Cybersecurity company. | |
 Nanoflex Robotics | Nanoflex Robotics AG is a Swiss ETH Zurich spin-off founded in2021 by Matt Curran, Bradley Nelson and Christophe Chautems. It develops the Remote Intervention System, combining a mobile electromagnetic field generator, ultra-flexible magnetically steerable guidewires and catheters, robotic advancement and a control console for endovascular procedures. Its longer-term neurovascular application is remote mechanical thrombectomy for ischemic stroke. Current development initially targets bedside peripheral vascular interventions, followed by control-room and teleoperated procedures. In2025 the company reported preclinical animal thrombectomy across the Atlantic and within Switzerland, plus porcine peripheral stenting; animal feasibility is distinct from human clinical efficacy. The European Commission’s current REACT project states clinical validation, regulatory approval and manufacturing readiness remain project objectives for2026–2028. The2023 first-in-human/FDA submission timetable was a plan, and ISO13485 quality-system certification does not establish device marketing approval. No current FDA clearance or CE marketing authorisation is established by the reviewed primary sources. The platform is described as AI-compatible and a Brainomix collaboration is developing AI-assisted navigation; the research partnership is not an investment. Public leadership includes CEO/co-founder Curran, mentor/co-founder Nelson, independent director Per Vegard Nerseth and CRO Chanel Allen-Megahey. Chautems announced his transition from CTO to non-executive director. A February2023 Series A secured an initial USD12million, led by Ascend Capital Partners with Kinled Holding and Mountain Labs. Innosuisse grants received in2023 comprised CHF2.5million and CHF400,000. A June2026 EIC blended-finance selection announced a EUR2.5million grant and EUR10million proposed equity; CORDIS later records a signed EUR2,498,971.85 REACT grant, while cash disbursement and equity closing remain unverified. | Glattbrugg, Opfikon, Zurich, Switzerland |
 Nanogram | Builds a mobile social platform for creating, playing and sharing short casual games. Users describe a game to an AI creation tool, remix existing games and discover playable creations in a swipeable feed. Games run inside the platform without separate downloads; its tools also support making games in Discord chats. | |
 NanoH2O | | |
 NanoLock Security | | |
 Nanonets | Nanonets operates in AI. | |
 NANOPLUME | Develops bio-based aerogel insulation made from nanoporous biomaterials. Its lightweight, thin insulating materials target cold-chain packaging and transport, as well as buildings, to reduce energy use and material bulk. | |
 Nanoramic | Nanoramic develops advanced materials for lithium-ion battery electrodes. Its Neocarbonix Slurry Precursor replaces conventional binders and additives with a conductive composite mesh, enabling PFAS-free battery materials and manufacturing without conventional NMP solvents. The drop-in technology works with existing production equipment and supports major cathode chemistries and silicon-rich anodes for electric vehicles, stationary storage, consumer electronics, drones, power tools and other applications. Founded out of MIT, the Massachusetts company combines nanocarbon research, pilot manufacturing and global production partnerships. | |
 NanoRep | | |
 NanoSyrinx | Company operating in Biotech & Life Sciences. | |
 Nanotronics | Industrial AI inspection. | |
 NanoVoxel | NanoVoxel GmbH is a Vienna contract manufacturer that designs and produces high-precision micro-components for medical devices, biotechnology, electronics and industrial engineering. It combines two-photon polymerization 3D printing with micro-injection molding, casting, micro-assembly and engineering consulting, choosing processes and materials for customers’ prototypes and larger production runs. Its capabilities cover complex three-dimensional structures, narrow channels and small features that are difficult to make with conventional machining. Applications include microfluidic chips and masters, micro-endoscopes, valves, microneedles, dispensing nozzles, microconnectors and miniature mechanical components. It also provides dimensional analysis using techniques such as laser 3D profilometry, scanning electron microscopy and micro-computed tomography. Registered in Austria in 2022, NanoVoxel serves researchers and product developers rather than selling an independently approved clinical therapy or diagnostic system. | |
 Nanox (Zebra Medical) | Company operating in Healthcare. | |
 Nansen | Nansen operates in Crypto & Web3. | |
 Nantero | Hardware & Semiconductors company. | |
 NaroIQ | Cologne-based financial technology company building digital infrastructure for launching and administering ETFs and investment funds. NaroIQ combines modular, API-first software with fund operations to help asset managers and fund administrators issue ETFs while retaining their existing partners and value chain. Chris Puellen and Nils Krauthausen founded the company in 2022. Its public team covers portfolio management, indexing, fixed income, product and business development. Subsidiary NaroAM received investment-firm authorization in November 2025. NaroIQ announced a €2.7 million pre-seed round in March 2024 co-led by La Famiglia and Discovery Ventures, followed by a June 2025 seed financing led by Magnetic Capital. NaroIQ is a fund infrastructure business; the assets administered for customers are separate from capital invested in the company. | Cologne, Germany |
 Narrative BI | No-code analytics that generates actionable data insights. | |
 Narrator | | |
 Narrator | | |
 Narvar | Narvar operates in Logistics & Supply Chain. | |
 Nas Academy | | |
 Nas Daily | Turn your idea into a business in minutes. Nas.com helps you create, launch, and sell. | |
 Nas.com | Company operating in E-Commerce & Marketplace. | |
 Nash | Nash operates in Crypto & Web3. | |
 Nash | | |
 Natera | | |
 National Cycling League | Media & Entertainment company. | |
 NationBuilder | NationBuilder operates in SaaS. | |
 Native Security | A cloud-security company providing a control plane to enforce security architecture and defenses across major public clouds. | |
 Nativo | Company operating in Marketing & Advertising. | |
 Natter | Conversational intelligence platform | UK, US |
 Natural AI, Inc. | Company operating in Fintech. | |
 NatureBox | Healthy snack subscription. | |
 Nautica Technologies | Nautica Technologies operates in Hardware & Semiconductors. | |
 Nautilus | Nautilus operates in Mobility & Transportation. | |
 Nautilus Biotechnology | | |
 Nautilus Labs | | |
 Nauto | Company operating in Mobility & Transportation. | |
 Nava | Provides cloud infrastructure for AI workloads, combining GPU computing, AI-oriented data centers, orchestration and inference services. | |
 Navan | Streamline your corporate travel management and expense processes in one app. Save time, gain efficiency, and reduce costs with this powerful, all-in-one solution. | Paris, France · Berlin, Germany |
 Navattic | | |
 Navenio | Company operating in Healthcare. | |
 Navidence | Navidence develops AI-native software and professional services that help healthcare and life sciences researchers design studies and determine which real-world health data is suitable for them. Its platform creates and curates Computable Operational Definitions, standardized human- and computer-readable descriptions of diseases, treatments, outcomes and other study elements. Researchers reuse these definitions to align study design, evaluate data suitability and make analyses more consistent, transparent and reproducible across clinical research studies and trials. | |
 Navier | Agent-driven engineering software company (Navier AI). | |
 NavigateAI | An AI copilot for field workers that supports instruction, upskilling and quality verification while physical work is performed. | |
 Navini Networks | | |
 Navion Neurosciences | Develops precision sodium-channel medicines for neurological disorders, initially focusing on genetic epilepsies and chronic neuropathic pain. Its NaViGATion discovery platform combines AI-enabled chemistry, structural biology, human disease biology and ion-channel expertise to find compounds that selectively modulate disease-related neuronal firing. | |
 Navro | Company operating in Fintech. | |
 Nawy | PropTech company. | New cairo, Cairo, EG |
 Naya Homes | Company operating in Travel & Hospitality. | |
 Nayya | Fintech company. | |
 NBCL | NBCL (Novel Biomarkers Catalyst Lab) develops and manufactures point-of-care immunoassays and diagnostic instruments in Nijmegen, the Netherlands. Its CONNECT analyzer measures intact parathyroid hormone from a whole-blood sample in about five minutes, bringing biochemical information into the operating room during parathyroid surgery. Disposable cartridges, barcode scanning, calibration and quality controls support testing without routine sample preparation or a central laboratory workflow. The company also develops immunoassays and provides assay-development and production expertise. CONNECT is used in hospitals across Europe and other EMEA markets. Its US market entry remains under development, and NBCL states that its intraoperative PTH test is not FDA-cleared or approved for US sale. A separate EFRO-supported EAGLE-EYE application for rapid assessment of parathyroid function is still undergoing technological development and clinical validation. | |
 nChroma | | |
 NcodiN | Hardware & Semiconductors company. | |
 NCX | Company operating in Climate & Energy. | |
 NDEA | Company operating in Manufacturing. | |
 nebenan.de | Company operating in Social & Community. | |
 Nebex | Defense & Space company. | |
 Nebia | | |
 Nebula Genomics | Company operating in Biotech & Life Sciences. | |
 Nebulock | Cybersecurity company. | Boston, MA, US |
 Nebulock | | |
 Nectar | | |
 Nectar Sleep | Company operating in Consumer. | |
 Nectome | | |
 Needle | Needle operates in SaaS. | |
 Neeva | | |
 Neighbor | Neighbor operates in Social & Community. | |
 Neighborly | Neighborly operates in Consumer. | |
 Neko Health | Preventive healthcare via broad, non-invasive body scanning, shifting from treating symptoms to preventing disease. Co-founded by Spotify’s Daniel Ek. Stockholm. | Stockholm, Sweden |
 Nektar | Company operating in SaaS. | |
 Nelly | Nelly operates in Healthcare. | |
 Nema | Nema operates in Consumer. | |
 NENNA.AI | Berlin enterprise AI privacy software company offering a shared interface to generative AI models and tools that mask sensitive information before sending it to external models. Its products support AI access controls, document protection, browser monitoring and organization-managed AI workflows. | |
 Neo Agent | Builds AI agents that automate IT service-desk work for managed service providers. Neo integrates with ticketing, remote monitoring, documentation and Microsoft 365 systems to triage requests, resolve routine issues, onboard users and perform scheduled checks, with configurable approvals and activity records. | |
 Neo Cybernetica | Robotics & Automation company. | |
 Neo Financial | Neo Financial operates in Fintech. | |
 Neo-Bionica | Neo-Bionica Pty Ltd is an Australian neurotechnology contract development and manufacturing company established in July 2021 as a joint venture between the Bionics Institute and the University of Melbourne. Its Australian Business Register entry identifies ABN 78 645915699, active from 1 July 2021. Based at St Vincent’s Hospital Melbourne in Fitzroy, with a team in the United States, it helps innovators turn implantable and wearable medical-device concepts into engineered prototypes, devices for first-in-human studies and clinical-grade manufacturing processes. Its capabilities include bioelectronics, neural interfaces, electrode fabrication, implantable power and wireless systems, firmware, miniaturisation, computational modelling, system integration, high-reliability assembly, hermetic packaging and precision machining. The company reports an ISO 13485-certified quality system and ISO 7 cleanrooms, alongside laser seam welding and hermeticity testing. Its work is relevant to neuroscience and deep technology through active implantable neurotechnology, brain-computer interfaces, neurostimulation and bionic medical devices; engineering and manufacturing capability does not establish clinical approval of every client’s device. The current main directory names 18 leadership, engineering and board members, including CEO Ludovic Labat and chair Emma Cleary. White-paper author Gil Rind is documented with a qualified published affiliation because he is absent from the current main directory. Former CTO Uli Gommel states that he ended the role in April 2026; founding chair Lusia Guthrie is recorded historically. Breakthrough Victoria announced a specific AUD 5 M convertible-note investment on 16 May 2024. Separate public support includes an AUD 4 M Victorian Higher Education State Investment Fund facility/research/voucher allocation at the 2021 opening and a federal Industry Growth Program Project Andromeda grant of AUD 250 K excluding GST, announced 9 January 2025. These government grants are recorded separately from the convertible note. A published client testimonial about securing 1 M belongs to Kali Healthcare, and early Ian Potter Foundation funding went to the Bionics Institute’s predecessor project; neither is extra Neo-Bionica equity financing. | Fitzroy, Melbourne, Victoria, Australia · United States |
 neo.tax | Company operating in Fintech. | |
 Neo4j | Data & Analytics company. | |
 Neobank Zolve | A financial-services platform helping global citizens establish banking and credit access after moving to the United States. | |
 NeoCarbon | Company operating in Climate & Energy. | |
 NeoDocs | | |
 NEOintralogistics | NEOintralogistics operates in Robotics & Automation. | |
 Neon | Serverless Postgres. Goldi alias Neon. | |
 Neon | | |
 Neon | | |
 neoncoral | | |
 Neophotonics | | |
 Neoplants | Company operating in Biotech & Life Sciences. | |
 Neople | AI company. | 's-Hertogenbosch, Noord-Brabant, NL |
 Neoscale | | |
 Neotas | Enterprise Software company. | London, United Kingdom · London, GB · New York, NY, US |
 Neotaste | Consumer company. | |
 Neoterra India | Neoterra India develops solar-compatible air-conditioning systems for homes and businesses. Its Smart Solar AC can use compatible solar power directly, switch to grid electricity when needed and integrate with configured solar and battery systems. The product offers adjustable cooling capacity, Wi-Fi control and air filtration. Neoterra combines equipment with site assessment, installation and after-sales support, aiming to make cooling more affordable and reduce the grid electricity needed by Indian households and commercial customers. | |
 neotiv | Magdeburg digital-health company translating neuroscience and dementia research into mobile cognitive assessments. Its software measures memory performance to support clinical assessment and monitoring of early cognitive impairment, including Alzheimer’s-related changes, and provides tools for healthcare and research workflows. | |
 Nephroplus | Nephroplus operates in Healthcare. | |
 Neptune Mutual | | |
 Neptyne | | |
 Nerd Street | Esports and competitive gaming venues and media. | United States |
 Neros Technologies | Neros Technologies is the American robotics and advanced-manufacturing company operating neros.tech, founded in2023 by Soren Monroe-Anderson and Olaf Hichwa. The current website’s privacy notice identifies Neros, Inc. as the controller acting with its overseas subsidiaries; its financing releases use Neros Technologies. These are source-proved names of the same operating platform, not evidence of an unrelated second company. The existing NerosInc alias record is retained with protected imported provenance, while this existing NerosTechnologies record receives the full current brand profile. No legal company merger, share transfer or duplicate parent is inferred.
The company designs and manufactures robotic defense systems with a domestic/allied component supply chain and manufacturing operations in Torrance, previously El Segundo. Its own August2026 financing release identifies Archer AI autonomy, Bandit counter-UAS and coordinated multi-asset control; these establish AI/robotics/deep-tech relevance. Product names, planned deployment and production goals are issuer claims, not independently verified field performance, clinical approvals or additional financing. Government procurement capacity and commercial drone orders are excluded from investment-round cash. September2026’s announced USD100M order and earlier up-toUSD500M Army contract are not venture financing.
Public team scope: current co-founder/CEO Soren Monroe-Anderson and co-founder/CTO Olaf Hichwa; issuer-published COO Sean Wood and VP Operations David DiDomenico; explicitly external Senior Advisor Phil Alden; Felix Pomerantz’s self-published finance/operations company affiliation, exact rank unpublished; and Earl G. Matthews’ historical2024 business-development/legal leadership. Sean’s historical2024 Head of Hardware capacity is recorded separately from his later COO role. No complete private staff directory is published, so this is the verified public source roster rather than a claim to enumerate all employees. Named genuine founder photographs are preserved as original issuer-hosted interview-thumbnail compositions, without cropping, fabricated headshots or misleading reassignment. Individually named Sequoia avatars were visually identified as drawings and rejected. Five other public people have documented authentic-portrait gaps. Appointment days are unknownNULL; historical roles are labelled in their titles rather than presented as current.
Financing audit: the CEO’s May20,2024 primary announcement reports USD10.9M combined across pre-seed and seed, not USD10.9M standalone seed. Separate pre-seed and seed event records therefore carry NULL standalone amounts, with combined disclosure retained in evidence and no duplicate aggregate cash record. Cantos’ own portfolio confirms Fund3/pre-seed lead; the issuer identifies Sequoia seed lead. The CEO’s March17,2025 primary article reports USD35M SeriesA led by Vy Capital US with Sequoia, Interlagos, D3 and personal investor Keller Rinaudo Cliffton. The issuer’s November10,2025 release explicitly reports USD75M SeriesB closed, led by Sequoia with Vy Capital US and Interlagos. The existing canonical USD250M SeriesC round17156 announcedAugust11,2026 is retained, with Sequoia and American Strategic Technology Fund co-leads; Interlagos, Valor Equity Partners, Allen & Company, Thiel Capital, Spark Capital and Dylan Field are named followers. Unknown individual tickets and subscribing fund allocations remainNULL.
Protected imported duplicates: NerosInc rounds17137 and17138 also reference the same August2026 SeriesC, while17137 was mislabelled SeriesB with year-only date. All three old round IDs, all15 old participation IDs, all original cash values and three GoldilocksDeal references are preserved. The duplicate alias records are explicitly labelled as imported references and excluded from unique financing aggregation; they do not prove two additional250Mraises. Their original source claims remain intact. Imported Stanford StartX participation does not establish actual ASTF identity: the company’s own source names American Strategic Technology Fund, and SEC identifies American Strategic Technology Fund LLC with ASTF Neros I LP/GP LLC, distinct from Stanford StartX. No protected financial graph is silently reassigned.
New exact checks are added only for full existing buyer profiles and personally named investors already identified. Missing full legal-manager/profile dependencies, including ASTF, Interlagos and Vy Capital US, remain queued; no bare new manager or guessed parent/subsidiary buyer is created. Peter Thiel’s seed participation is personal per the CEO’s wording, distinct from institutionally named Thiel Capital at SeriesC. Dylan Field’s named SeriesC check is personal, not an inferred Figma corporate investment. Cantos canonical1651 is reused, preserving its protected4179alias; Sequoia canonical1539 and D3 canonical10416 are reused. All unproved closed fund allocations and individual checks remain unpublished. | Torrance, California, United States |
 Neros, Inc. | Protected historical imported alias of the neros.tech operating platform. The current own privacy notice identifies Neros, Inc.; the own financing release uses Neros Technologies. Full current source-based profile, authentic logo and public team are maintained on existing NerosTechnologies. This alias is retained to preserve all protected financial and Goldilocks source references; it is not a second independently financed startup.
Imported rounds17137 (250M mislabelledSeriesB/year2026) and17138 (NULLamount SeriesC with the identical own August2026 source) reference the same actual USD250M SeriesC as canonical NerosTechnologies17156, announcedAugust11,2026. They are duplicate imported financing references, excluded from unique fundraising aggregation. All cash values, dates, round/IP IDs and protected raw Goldilocks claims remain preserved, with no silent merge, deletion or cash clearing. Imported StanfordStartXFund labels do not prove AmericanStrategicTechnologyFund(ASTF) identity; exact institutional subscriber correction needs the separately verified full legalmanager, not a name-based substitution. | |
 nervana | Congratulations to Intel on their acquisition of Nervana. This photo is from the last board meeting at our offices; the Nervana founders — from right to left: Naveen Rao, Amir Khosrowshahi and Arjun Bansal — pondered where on the wall they may fall during M&A negotiations. We are now free to share some of our perspectives on the company and its mission to accelerate the future with custom chips for deep learning. I’ll share a recap of the Nervana story, from an investor’s perspective, and try to explain why <i>machine learning is of fundamental importance to every business over time. In short, I think the application of iterative algorithms (e.g., machine learning, directed evolution, generative design) to build complex systems is the most powerful advance in engineering since the Scie | |
 NervGen Pharma | NervGen Pharma develops neuroreparative medicines intended to restore nervous-system function after spinal cord injury and other neurological damage. | |
 Nervonik | Develops peripheral nerve stimulation systems for chronic neuropathic pain. Its investigational platform combines electrical stimulation with physiological sensing to personalize therapy, using implantable leads to record nerve-response biomarkers. The devices are engineered for movement, with a focus on wearability, lead stability and durability. | |
 Nest | | |
 Nest Genomics | Biotech & Life Sciences company. | |
 Nest Health | Nest Health operates in Healthcare. | |
 Nested | Nested operates in PropTech. | |
 Nestwell | Nestwell, operated by Go Nestwell Inc. in Santa Monica, California, is a digital environmental-health platform helping households assess and improve exposures in their homes. Its Nestwell Score combines address and property information with percentile-based environmental metrics, nearby hazard sites and live geospatial alerts from public data sources. Customers can order kits for certified partner-laboratory testing of water, air, dust, soil, radon and mold, view measured results and prioritized guidance, and find filters, purifiers and other remediation products. The company’s science framework concerns the exposome and respiratory, developmental and broader environmental health; its reports screen home exposures and are not medical diagnoses. Its privacy policy describes AI-powered chat and backend AI service providers, while its published score methodology is percentile-based. Founder and CEO Ben Parens reported an oversubscribed pre-seed financing closed February2,2026, with the amount and buyers undisclosed. Nestwell later acquired Dwelling Health, a Healthworx Studio venture, and appointed Shiv Gaglani as a strategic advisor. Healthworx Studio lists Nestwell among companies that acquired studio-created assets. Treehub by AI Health Fund separately names Nestwell as a first-check investment; exact allocation and funding-round assignment are unpublished. | Santa Monica, California, United States |
 Net Purpose | Data & Analytics company. | |
 NetBeez | | |
 Netbox Labs | Infrastructure & Cloud company. | |
 Netdata | Netdata operates in Data & Analytics. | |
 Neteera Technologies | Neteera Technologies Ltd. is an Israeli medical-technology company developing contactless, radar-based remote patient monitoring. Its sub-terahertz micro-radar detects small bodily movements without cameras, microphones, wearables or attached skin sensors. The platform combines measured vital signs with AI-powered insights, baseline analytics and alerts for clinical care teams, including hospitals, nursing facilities and home monitoring. This is AI-enabled medical sensing and semiconductor deep technology; a brain-interface or standalone neurological diagnosis is not asserted. The FDA cleared its Class II 130H-Plus vital-sign monitoring sensor on February9,2024 under K231733 for spot and continuous heart-rate/respiration-rate measurement in adult patients and bed-exit information. The company reports European ClassIIa CE MDR certification in March2025. Clearance applies to the named device and intended use, not unrestricted approval of every analytics claim. Isaac Litman is founder and CEO. Its public directory names eleven executives/operators, four additional directors and two external advisers; fractional and advisory roles are qualified. Verified financing includes a March2020 Series A investment with unpublished amount/day, approximately USD13 million Series B closed April25,2023 and approximately USD6.7 million additional Series B extension closed October31,2023. The later USD19.7 million cumulative Series B figure is their combined total and is not another raise. Earlier secondary-only funding amounts conflict and are retained as research gaps. Historical Aescuvest platform checks are distinct from ACP Healthtech’s later manager portfolio association, which does not prove an additional priced round. | Jerusalem, Israel · Lewes, Delaware, United States (published US office) |
 Netezza | | |
 Netic | AI agents for home-services businesses. Founders Fund led Series A and $23M Series B (Nov 2025). | San Francisco, California |
 Netlify | Netlify operates in Developer Tools. | |
 Netmagic | Company operating in Infrastructure & Cloud. | |
 Netmaker | | |
 NetNow | Infrastructure & Cloud company. | New York, NY, US |
 Netography | Netography operates in Cybersecurity. | |
 Netomi | | |
 Netop | | |
 NetQin | | |
 Netrasemi | Designs semiconductor chips for edge AI and embedded computing applications. | |
 NetScaler | | |
 Netskope | Provides cloud and network security software that protects enterprise users, applications and data through secure access service edge and zero-trust controls. | |
 Netspeak Games | Company operating in Gaming. | |
 NetSpring | | |
 Nettle | Company operating in Insurance. | |
 Network Bio | Biotechnology company; raised $50M in 2026 with Founders Fund among backers. | |
 Network Bio | | |
 NetworkOcean | | |
 Neubility | Neubility develops and operates autonomous robots for last-mile delivery, patrol and industrial tasks. Its camera-based AI navigation technology, NeuOn robotics kit and Neubility Control Center connect robot hardware with mission monitoring, remote response and fleet operations through a robot-as-a-service model. Its products include wheeled delivery and patrol robots, and it is developing humanoid and quadruped solutions with partners including Unitree. The business focuses on physical AI and robotics. | |
 Neubond | Develops wearable neuromuscular interfaces and a connected rehabilitation platform for stroke recovery. Its bracelet detects muscle activation and provides biofeedback to help patients reconnect movement intention with muscle activity, while clinicians monitor rehabilitation remotely. | |
 Neul | Company operating in E-Commerce & Marketplace. | |
 Neumirna Therapeutics | Neumirna Therapeutics is a Copenhagen-based biotechnology company developing RNA medicines for neurological disorders. Its platform targets microRNAs with antisense oligonucleotides to address disease mechanisms. Its lead program, NMT.001, focuses on drug-resistant epilepsy, with a further program in Parkinson's disease. Founded by neuroscience and RNA biology specialists, the company operates across Copenhagen, Basel and Boston. | |
 Neumora Therapeutics | | |
 Neumora Therapeutics, Inc. | A clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric, neurodegenerative and related brain diseases. | |
 Neura Health | Company operating in Healthcare. | |
 Neura Robotics | Company operating in Robotics & Automation. | |
 Neuracore | AI company. | |
 Neural Galaxy | Brain science and medical technology company developing individualized functional brain mapping and non-invasive neuromodulation. Its personalized Brain Functional Sectors platform maps individual brain networks to guide precision stimulation research and clinical development for psychiatric and neurological disorders. Founded by Hesheng Liu, Guoping Feng, Robert Desimone and Coach Wei, it combines computational neuroimaging with neuroscience and medical hardware. | |
 Neurala | Neurala, Inc. is a Boston-based developer of brain-inspired vision AI for embedded and industrial products. Founded in 2006 by neuroscientists Max Versace, Heather Ames and Anatoli Gorchet, it commercialized research supported by NASA, DARPA and the US Air Force. Its patented Lifelong Deep Neural Network (L-DNN) uses complementary learning approaches inspired by the neocortex and hippocampus to support visual learning from limited examples and continued adaptation on edge devices. The current business licenses and integrates this technology into OEM hardware, software and manufacturing inspection systems; VIA is its industrial visual-inspection offering. The company publishes applications with FLIR, Sony Semiconductor Solutions and IHI, and identifies its headquarters at 308 Congress Street, Boston, Massachusetts 02210. A European subsidiary in Trieste is distinct from the Boston parent. The current public leadership directory identifies Anatoli Gorchet as co-founder, CEO and CTO; Max Versace is a co-founder and former CEO, with subsequent work at Analog Devices. Historical consumer robotics, drone and automotive applications are part of its development history. This company is distinct from Neurala Biosciences at neurala.co and Neura Robotics. Financing announcements establish separate $750,000 seed, $1.2 million follow-on, $14 million Series A and $12 million later financing events; cumulative fundraising figures are not additional rounds. Clinical treatment or regulatory clearance is not claimed for its industrial AI platform. | |
 Neuralk | AI company. | |
 Neuramatrix | Neuramatrix operates in Healthcare. | |
 NeuraWorx | NeuraWorx develops bioelectronic devices intended to improve cerebrovascular and glymphatic function. | |
 NeuReality | | |
 NEUREALITY LTD | | |
 Neurescence | Neurescence is a Toronto-based neuroscience technology company acquired by Bruker in 2022. It developed fiber-bundle miniature microscopes for simultaneous optical recording and stimulation across multiple brain or spinal-cord regions in freely behaving animals. Its Quartet and Chromatone systems support calcium imaging and optogenetics, while its research software incorporates machine learning for neuronal image analysis. Yasaman Soudagar, Sepideh Hashemi and Taufik Valiante are documented co-founders. Its original Canadian corporation was incorporated on August 18, 2014 and amalgamated into a corporation of the same name on November 30, 2022; Bruker’s acquisition announcement separately describes a 2015 founding. Neurescence received a USD100,000 Luminate accelerator investment through the second cohort selected in November 2018, as well as Canadian NRC research and youth-employment contributions. Bruker announced its acquisition agreement on November 14, 2022; subsequent Bruker materials confirm the acquisition, with financial terms undisclosed. The technology is for neuroscience research and preclinical applications. | |
 Neuro Event Labs | Neuro Event Labs is a Finnish medical technology company developing AI-assisted monitoring of epileptic seizures. Its Nelli system captures contact-free video and audio through a camera and microphone, uses machine learning to identify events indicative of motor seizures, and presents an interactive report for clinical review. The system supports monitoring at home and in hospitals and can include expert annotation services. Founded in Tampere in 2015, the company markets Nelli in Europe, the United Kingdom and the United States. | |
 Neuro42 | neuro42, Inc. is a San Francisco medical-technology company developing portable low-field magnetic resonance imaging, artificial intelligence and robotic guidance for neurological diagnosis and image-guided brain interventions. Its diagnostic MRI platform is FDA 510(k) cleared for neuroimaging; its interventional module is seeking regulatory clearance, so clearance is not asserted for the entire robotic platform. The company licenses MRI technology developed at Massachusetts General Hospital and describes more than 40 patents supporting its platform. Its published leadership and scientific/clinical advisors are recorded with source-qualified historical appointments where its directories differ. Financing records distinguish closed equity rounds, undisclosed personal investments and later offering disclosures under review. | San Francisco, California, United States |
 NeuroBell | NeuroBell is an Irish medical-device and AI neurotechnology company developing portable neonatal electroencephalography monitoring and automated seizure alerts for neonatal intensive care units. NeuroBell Limited is the Irish legal company, CRO743738 and VATIE4169254PH, based in Ballincollig, Cork; its own footer also identifies a US NeuroBell Inc. office in Fort Wayne without establishing that entity as the subscriber or issuer of every funding transaction. Founders Mark O’Sullivan, Alison O’Shea and Colm Murphy emerged from University College Cork and the INFANT Research Centre. Research began in2015, an Enterprise Ireland university commercialisation project ran in2021–2022, and the company’s own history dates spinout and EUR2.1M seed funding to2023; UCC announced that same closed round January8,2024. The Luna system combines a wireless EEG amplifier, web-based EEG review software and an Incereb Neon10 headcap. Deep-learning seizure detection and annotated neonatal EEG data are described by the developer; clinical accuracy or improved patient outcomes are not independently asserted here. Its current product page expressly says the product is not available for commercial sale, and its story says FDA clearance and US launch are anticipated in2026 while clinical validation/regulatory submission continue. Those expectations are not marketing authorization. ISO13485 certification is the company’s stated quality-management status, not product clearance. Eighteen named current leadership, advisers and staff are published. A USD5.5M round announced June30,2026 supports US expansion; the reported EUR4.8M equivalent is not a separate raise. University research grants, clinical partnerships and a Parkview pilot competition prize are distinct from company equity cash. | |
 Neurobiome | Neurobiome is an Oregon biotechnology company developing Gut-Brain Chip technology to study microbiome-derived compounds that affect neuronal activity. Its microfluidic platform uses dynamic flow and electrophysiology for high-throughput screening and aims to support discovery of neuroactive molecules relevant to gut-brain biology and neurodegenerative disease research. The company's website identifies the business as Neurobiome LLC and lists Maude David as Managing Partner, with Kenton Hokanson and Tim Vogel as Partners. These are company leadership titles. Neurobiome received backing through Elevate Capital's Oregon commercialization Innovation Gap Fund I, confirmed in the manager's October 2021 announcement and the current state portfolio. The reviewed sources do not disclose its investment amount, a complete employee roster or an approved treatment. | |
 NeuroBionics | NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate with the human body. | |
 neurocare group | Personalized mental-health care and digital therapeutics platform incorporating neuromodulation and neurofeedback. Mixed clinical provider/platform exposure, distinct from a pure implant device manufacturer. | |
 NEURODE | Neurotechnology company developing a wearable headband combining transcranial random-noise stimulation and fNIRS brain monitoring, with an app for executive-function tracking. Its initial focus is ADHD. The company states that its platform remains in clinical development and has not received FDA, TGA, or comparable marketing authorization. | Sydney, Australia |
 NeuroEquilibrium | Operates clinics for vertigo, dizziness and balance disorders and develops diagnostic devices and cloud-based tools for remote assessment. | |
 Neurofenix | Neurofenix operates in Healthcare. | |
 Neurogene | Clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its EXACT platform uses microRNA-based circuits to regulate transgene expression and address overexpression toxicity. Its lead investigational AAV gene therapy, NGN-401 for Rett syndrome, is being evaluated in the Embolden registrational trial. It operates an in-house gene therapy manufacturing facility in Houston and became publicly traded on Nasdaq as NGNE following its December 2023 reverse merger with Neoleukin Therapeutics. | New York, New York, United States · Houston, Texas, United States |
 NeuroHarmonics | NeuroHarmonics is a London neurotechnology company developing non-invasive, low-intensity focused-ultrasound systems that stimulate small targets deep in the brain. An array of individually controlled transducers makes acoustic contact through the hair, while MRI-derived anatomy and computational acoustic models guide ultrasound through the skull onto selected neural circuits. The approach is non-ablative and intended to produce temporary, repeatable modulation without implants, surgery or head shaving. Its first patient application is essential tremor: a sham-controlled proof-of-concept study at University College London Hospitals targets the ventral intermediate nucleus of the thalamus to assess safety, tolerability and preliminary target engagement. The study has MHRA no-objection and ethics review and is listed as recruiting; it is not designed to establish lasting clinical benefit. A separate healthy-volunteer study targets the lateral geniculate nucleus and records visually evoked brain responses with EEG. The wider platform is intended for additional neurological and psychiatric research applications, with a longer-term ambition for accessible outpatient and wearable systems. Its devices remain investigational, with no approval, clearance or certification for commercial sale or general clinical use, and safety and effectiveness have not been established. The UCL spinout builds on its founders’ ultrasound research begun in 2016. | London, United Kingdom |
 Neurolabs | Company operating in Biotech & Life Sciences. | |
 Neurolase | London medical-technology company developing a handheld surgical guidance system for brain-tumour operations. Its probe uses Raman spectroscopy and machine learning to classify molecular tissue signatures in real time, helping surgeons distinguish tumour tissue from healthy brain and assess tumour grade. The system is designed to provide visual and auditory guidance during resection without contacting or damaging the sampled tissue. Neurolase is developing its hardware and AI models toward further clinical validation and regulatory approval. Co-founders Monika Kott and consultant neurosurgeon Babar Vaqas combine commercial healthcare experience with clinical invention. | |
 Neurolentech | Neurolentech is an ISTA spinout based in Klosterneuburg, Austria. It provides patient-derived neuronal models and functional assays for neuroscience drug discovery, including epilepsy and autism. Its services combine electrophysiology, drug screening and transcriptional profiling across genetically diverse patient cohorts. It also supplies functional data for AI models in biology and neuroscience. Its founders include Carsten Pfeffer, Gaia Novarino and Christoph Bock. XISTA Science Ventures, then ISTcube, announced a seed investment in October 2021; ISTA subsequently reported a separate AWS Seedfinancing grant in 2022. Amounts were not disclosed in these sources. | |
 Neurolieve Biosciences | Neurolieve Biosciences is a London biotech developing NLV-01, an investigational biologic for peripheral neuropathic pain. Its bioengineered fusion protein is designed to selectively activate galanin receptor2 (GalR2) in peripheral nerves, aiming to provide pain relief and support nerve repair. The company describes a design that keeps the protein outside the brain to avoid central nervous system effects; these are development goals and preclinical findings, rather than proven clinical outcomes. The lead programme initially targets chemotherapy-induced peripheral neuropathy, with potential expansion into diabetic neuropathy and other peripheral pain conditions. The company reports that discovery and lead selection are complete, preclinical validation is in progress, IND-enabling work is the next milestone and clinical development remains future work. Its own footer explicitly states that NLV-01 has not been approved by any regulatory authority. Neurolieve was co-founded with NLC and LifeArc and develops technology originating from LifeArc’s collaboration with University of Bristol pain researcher David Wynick. NLC provides venture-building support and backing; LifeArc contributes protein engineering, licensed commercial rights and continuing laboratory collaboration. | London, United Kingdom |
 Neuromod Devices | Neuromod Devices is an Irish medical technology company developing and commercialising non-invasive neuromodulation for tinnitus. Its Lenire device combines customised sound delivered through headphones with mild electrical stimulation of the tongue to reduce tinnitus symptoms. Lenire received US FDA De Novo authorisation in 2023 and is offered through trained audiology and ENT clinics in the United States and Europe. The company conducts clinical and real-world research on bimodal stimulation and tinnitus care. | |
 Neuron7.ai | Company operating in AI. | |
 Neuronetics | Public U.S. medical technology and interventional mental-health company (Nasdaq: STIM), incorporated in Delaware in2003 and headquartered in Malvern, Pennsylvania. It develops and markets the NeuroStar Advanced Therapy transcranial magnetic stimulation system, using noninvasive magnetic pulses for prescription treatment within its cleared indications. FDA510(k) clearances cover adult major depressive disorder, anxiety symptoms accompanying adult MDD, adjunct treatment for adult obsessive-compulsive disorder, and adjunct MDD treatment for adolescents aged15–21; clearance is indication-specific. Neuronetics acquired Greenbrook TMS on December9,2024 and operates its U.S. interventional psychiatry clinic network as a wholly owned subsidiary, offering TMS and SPRAVATO therapies. Dan Reuvers became President and CEO in March2026; current leaders include CFO Nir Naor, Cory Anderson as EVP and General Manager of Greenbrook, and sales SVP Rob Greene. Its neuroscience relevance rests on neuromodulation devices, clinical evidence, patient registries and care delivery; planned neuronavigation collaborations and workflow integrations do not establish additional cleared indications. Verified financing includes venture rounds, a2018IPO, subsequent public equity offerings and actual debt draws. Madryn became a major shareholder through Greenbrook debt conversion and merger share exchange; this noncash ownership event is distinct from new issuer cash funding. Geoffrey Grammer is Chief Medical Officer of both Neuronetics and Greenbrook, as explicitly identified in the company’s July28,2026 announcement. | Malvern, Pennsylvania, United States |
 Neurophos | Neurophos operates in AI. | |
 Neuros | Company operating in Manufacturing. | |
 Neuros Medical | Neuros Medical develops and commercializes Altius, an implanted peripheral nerve stimulation system for chronic post-amputation pain. A nerve-cuff electrode and pulse generator inhibit pain-signal transmission near the amputation site; patients activate on-demand treatment using an external controller. FDA approval covers management of chronic, intractable phantom and residual lower-limb pain in adult amputees. Its Series D supports U.S. commercialization and further product development. | |
 Neurosity | Neurosity, Inc. is a Delaware neurotechnology company incorporated April20,2018, developing wearable EEG brain-computer interfaces and associated software. Its Crown headset records electrical brain activity for neuroadaptive audio, feedback applications and developer integrations. The company publishes JavaScript/Python SDKs and brain-signal-processing tools. Its focus, meditation and mental-state objectives are issuer product claims; this profile does not present them as proven treatment efficacy or regulatory approval. The current public About page names founders AJ Keller (CEO) and Alex Castillo (CTO). Additional engineers, a neuroscientist and an international project manager appear in its dated2023 securities disclosure; later employer sources make several affiliations explicitly historical. Native2022 SEC disclosure reports USD4,981,188 securities sold to25investors in an equity/debt offering, without a disclosed priced-round stage or final closing day. A later Wefunder SAFE campaign was last funded in January2024; conflicting current raised counters318,609 and343,609 are preserved as an unresolved amount, and its50,000target/1,235,000maximum are not recorded as cash raised. Its declared venture backers are source-qualified separately from those transaction-specific disclosures. | Brooklyn, New York, United States |
 Neurosoft Bioelectronics | Neurosoft Bioelectronics is an EPFL spin-off developing soft, stretchable brain-computer interfaces that rest on the cortical surface without penetrating brain tissue. Its electrodes record and stimulate neural activity while conforming to the brain. SOFT ECoG is designed for intraoperative and short-term subdural recording and stimulation, including epilepsy surgery mapping. MINDZ is a folded electrode interface intended for deployment through a small skull opening, initially to help localize drug-resistant epileptic activity. Its development programmes also include SOFT TINNIT, an implantable closed-loop neuromodulation system for severe tinnitus, and Synapsuit, which combines neural decoding with a wearable exosuit for people with impaired arm and hand movement. The company is developing AI models for decoding cortical signals and discovering neurological biomarkers. Headquartered in Geneva with a US subsidiary in New York, it operates a Swiss medical-device production line and holds ISO 13485 certification. In May 2026 it reported testing its interfaces in ten patients across ongoing studies at UTHealth Houston and UMC Utrecht. Its brain interfaces remain investigational and are not yet available for sale in the United States or Europe. | Geneva, Switzerland |
 Neurosom | Neurosom is a Eugene, Oregon neurotechnology company developing a precision brain-health platform combining EEG measurement, AI sleep-stage analysis and closed-loop transcranial electrical stimulation. Its wearable Sleep WISP is being studied for improving restorative sleep and related cognitive outcomes. NEAT, its neural-network EEG sleep-scoring software, has FDA 510(k) clearance under K250058, issued April 10, 2025 to affiliate Brain Electrophysiology Laboratory Company, LLC; this clearance is for the software's sleep-staging indications and does not establish approval of a dementia-prevention therapy. Neurosom was incorporated in Delaware on July 21, 2021 and licenses technology from BEL, a distinct affiliate under common control. Its public management team includes CEO Viral Sheth, Chairman and Chief Science Officer Don Tucker, CTO Phan Luu, Commercial Leader Dee Dee Nunes, CMO Corin Tucker and Accounting Manager Tess Pablo Teittinen. The company also explicitly identifies Mount Sinai researcher Allison C. Waters as a Medical Advisor. A January 6, 2026 release announced an oversubscribed bridge round approaching closing, led by Portland Seed Fund's Intrepid Oregon Fund with Loomis Family Trust, OEN Angel Syndicate and ONAMI participation. Its earlier Regulation Crowdfunding offering was conducted through Neurosom SPV, LLC. The January release's planned $5 million seed round is a fundraising target; a completed seed closing is not established by the reviewed sources. NIH grants for related sleep technology are awarded to BEL rather than directly to Neurosom. | |
 Neurotrack | Neurotrack is the cognitive-health technology company legally NeuroTrack Technologies, Inc., a Delaware corporation founded in2012 (SEC CIK1577569), operating neurotrack.com. It develops digital cognitive screening and a cognitive-care platform for providers assessing mild cognitive impairment and dementia, arranging diagnostic pathways and care planning. Its current Smart Logic product describes adaptive assessment routing and care recommendations within clinical workflows. These are company product claims, not a claim of autonomous diagnosis, an independently validated comparative benchmark, FDA approval or a proven Alzheimer cure. An older2022 product announcement says FDA ClassII registered; registration is not equated with clearance or approval.
The scientific origins include visual paired-comparison/eye-tracking work by Emory-linked scientific co-founders Stuart Zola, Elizabeth Buffalo and Cecelia Manzanares. Emory licensed technology in2012; inventor-university research grants are distinct from company venture proceeds. The current company roster names seven executives and two scientific co-founders. Older chief scientists, clinical advisers and grant investigators are retained with dated historical scope. Remote staff are described as based across the US and Canada, alongside historical RedwoodCity corporate records. Unrelated neurotrack.tech consulting and NeuroTrack/Neuropulse programme homonyms are excluded.
Primary releases support a USD2M SeriesA announced26September2013, USD6.5M new financing27January2016, USD13.7M SeriesB20March2018, USD21M SeriesC11June2019 and USD10M unspecified-stage financing reported1November2022. A2014 SEC notice separately records USD1M debt/options sold. The USD9.5M January2016 headline is cumulative funding, not an additional2020 round. Duplicate historical source records are retained with explicit mirror/cumulative qualifications rather than summed as new cash.
Five exact NIA annual awards total USD3494935 (including USD3269678 across2019–2022 fast-track awardAG063672 and a separate2014 award). Notice-award amounts are not proof of bank disbursement or equity. ADDF publishes two distinct Diagnostics Accelerator projects of USD587890 and USD205100, with research instrument and award date unpublished; listed project dates are not cash closing dates. RockHealth publishes Neurotrack among its portfolio companies, without disclosing the check or round. Conditional grants, founder-university grants, aggregate lifetime funding and investor fund sizes are not additional company rounds. | Redwood City, California, United States (historical corporate location; current remote US/Canada team) |
 Neurotrack Technologies | See why health systems choose our clinically validated, FDA class II device for digital cognitive screening in primary care, virtual care, and care at home. | |
 Neurotrack Technologies | | |
 Neurovalens | Company operating in Healthcare. | |
 NeuroVision Imaging | NeuroVision Imaging, Inc. is a Sacramento healthcare technology company founded in2010, historically operating as NeuroVision Imaging LLC. Its current integrated platform combines BrainHealth Clinic telehealth cognitive care, Afina retinal imaging and Duritect blood-based biomarker development for neurodegenerative diseases. Afina is a cloud-based AI imaging pathway intended to identify retinal disease signatures and support treatment-safety monitoring; the company explicitly labels certain components investigational or under development and not FDA-cleared or approved. FDA records confirm Afina Release1.1 received510(k) clearance K181501 on November2,2018 for retinal-image importing, processing, display and autofluorescence measurement. The cleared software reports measurements for clinician interpretation and does not provide a specific clinical diagnosis; this does not establish clearance of an Alzheimer’s diagnostic claim or the company’s broader current biomarker platform. Research feasibility, clinical-service availability and device marketing authorisation are distinct. NeuroVision announced the acquisition of Durin Life Sciences on May12,2026, combining blood-biomarker programmes for Alzheimer’s, Parkinson’s and ALS with its retinal imaging and patient-care infrastructure; transaction consideration is undisclosed. CEO and co-founder Steven Verdooner continues to lead the combined company, and Durin majority owner Ric Edelman joined its board. Its current corporate website publishes seven directors; its own BrainHealth service publishes eleven operational leaders/staff and eight scientific advisers, with overlapping people reconciled. Historical scientific founders include Keith L. Black, Maya Koronyo-Hamaoui and Yosef Koronyo, associated with Cedars-Sinai retinal-amyloid research; their historical appointments are not assumed current executive jobs. A2016 Series B announcement confirms a USD5million lead investment from Wildcat Capital Management while reserving part of a USD10million financing for strategic investors. AMay2,2018 Series C completed an initial USD11.2million close toward USD15million; no additional USD15million cash event is inferred. Current primary investor materials also identify Labcorp, Gates Ventures, Tiny Orange Capital and Gaston Capital without round dates or allocations. The Alzheimer’s Drug Discovery Foundation reports two closed diagnostics projects awarded in2020 and2021; their funding instruments and payment timing require qualification. | Sacramento, California, United States |
 NeuroXT | NeuroXT develops artificial intelligence software that analyzes brain MRI scans and clinical information to support Alzheimer’s disease assessment and precision treatment research. Its NEXT-Cue product supports cognitive-decline assessment, NEXT-STAGE estimates regional tau burden from MRI for research, and NEXT-SCN studies synaptic integrity and responses to synapse-targeted therapies. The company collaborates with clinical research institutions to validate imaging biomarkers and predict individual treatment responses. | |
 Neusignal Therapeutics | Tokyo-based clinical-stage biotechnology company founded in April 2022 to develop treatments for dementia and other central nervous system disorders from Tohoku University research. Its lead candidate NTX-083 is an orally administered small molecule being developed for Alzheimer’s disease with a new mechanism of action. The company conducts clinical development, builds backup compounds and explores additional brain-disease targets. By June 2026 it reported completing single- and multiple-dose Phase 1 studies in healthy adults and planned a US Phase 1b study in Alzheimer’s patients; cognitive benefits and disease modification remain development goals. | |
 Neuvasq Biotechnologies | Neuvasq Biotechnologies is a Belgian biotechnology company founded in February 2021 as a spin-off of Université libre de Bruxelles and scientific founder Professor Benoit Vanhollebeke. It engineers Gpr124- and Reck-targeting Wnt surrogate antibodies intended to restore blood-retina and blood-brain barrier integrity. Its lead investigational molecule NVQ401 targets vascular retinopathies, including diabetic macular edema and wet age-related macular degeneration. A second preclinical programme explores neurological diseases associated with impaired neurovascular barriers. Current published leadership lists Denis Bedoret as Executive Director and Ralph Laufer as Chief Scientific Officer. The company reports preclinical research and potential indications; no marketing approval or proven clinical efficacy is asserted. Its June 22, 2021 announcement disclosed a EUR 20 million Series A led by Newton Biocapital I, comprising EUR 10 million public and EUR 10 million private investment, with the named institutions and unnamed business angels separately qualified. Non-dilutive Walloon Region support is disclosed without public amount, date or disbursement terms. The Belgian government CBE registry confirms exact legal entity NEUVASQ BIOTECHNOLOGIES, enterprise BE0762.966.663, active since February 5, 2021, with current public limited company form effective June 18, 2021. The registry also lists legal directors/representatives not all present in the marketing directory. The registry names Christine Franssen as permanent representative of Sparaxis SA (BE0452.116.307), while the current issuer biography names Christina Franssen and describes a Wallonie Entreprendre investment role. Sparaxis is not Wallonie Entreprendre. The Christine/Christina identity bridge and different representative/employer affiliations remain unverified; no legal alias or purchasing vehicle is inferred from the marketing subtitle. | Gosselies, Belgium |
 Neverland | | |
 Neverware | Enterprise Software company. | |
 Nevis | Company operating in Fintech. | |
 New Days | Healthcare company. | |
 New Lantern | New Lantern, Inc. is a San Francisco AI software company developing a cloud workspace for radiology. It brings worklists, medical-image viewing, dictation and reporting into one platform. Its Curie AI assistant helps prepare structured reports for radiologists to review and sign, while agentic worklist routing supports case assignment and workload management. The viewer supports mammography and PET imaging workflows, and its NL-Vox speech model supports radiology dictation. Founder and CEO Shiva Suri developed the platform after observing his mother’s fragmented radiology workflow. The company announced a completed USD19 million Series A on November 20, 2024, led by Benchmark, with Afore Capital, Neo, SV Angel and the Menlo-managed Anthology strategy among participants. Afore separately identifies its earlier pre-seed backing without a public amount or exact date. Position Ventures names the company in its own portfolio without identifying its round. New Lantern is relevant to artificial intelligence, medical imaging and healthcare software; workflow assistance is distinguished from autonomous medical diagnosis. This profile preserves its original Series A and personal-investor history. | San Francisco, California, United States |
 New Matter | | |
 Newfront | Commercial insurance brokerage; formerly Abe Labs. | San Francisco, California |
 Newfront | | |
 Newfront Insurance | | |
 Newleos Therapeutics | Newleos Therapeutics is a Boston-based clinical-stage neuroscience biotechnology company developing oral medicines for neuropsychiatric disorders. Its Roche-licensed pipeline includes NTX-1955, targeting GABAA-γ1 for generalized anxiety; NTX-1472, a V1a antagonist being studied in social anxiety; NTX-2001 (ralmitaront), a TAAR1 partial agonist being studied in substance use disorders; and NTX-1511 (basmisanil), targeting GABAA-α5 for cognitive impairment. These are investigational therapies, with efficacy and safety subject to clinical testing. Founded by Longwood Fund and neuroscience drug-development specialists Federico Bolognani and William Martin, Newleos launched publicly in February 2025 with a USD93.5 million Series A led by Goldman Sachs Alternatives. Timothy Noyes is current CEO, Federico Bolognani is co-founder and CMO, and Rohan Palekar became board chairman in July 2026. Christoph Westphal continues as a director after stepping down as executive chairman. | |
 NewLimit | NewLimit is extending human healthspan by unlocking regenerative potential. | |
 NewNew | Consumer company backed after a16z intro. | |
 Newport Media | Newport Media, Inc. operates in Media & Entertainment. | |
 Newronika | Newronika S.p.A. is an Italian neurotechnology and medical-device company developing adaptive deep brain stimulation for Parkinson’s disease and researching further neuromodulation applications. Founded in2009 as a spin-off of Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico and the University of Milan, its αDBS/AlphaDBS platform combines implanted neural sensing, a closed-loop stimulation algorithm, a clinician interface and patient remote. The latest commercial system integrates WebBioBank, its cloud platform for longitudinal neural data. The2025 financing announcement describes real-time neural data and machine-learning integration as a development aim, not proof of autonomous clinical decision-making or efficacy for every neurological indication.
The current primary directory lists nine leadership/functional members and seven scientific advisers, including ExecutiveChairman KeithCarlton, Co-Founder/CEO/CTO LorenzoRossi and ChiefMedicalOfficer IoannisU.Isaias. The legal issuer is NewronikaS.p.A., VATIT06399770962/REAMI-1890329; headquarters ViaTorquatoTasso1,20093 ColognoMonzese(Milan), with legal address ForoBuonaparte57,20121 Milan. The separately identified NewronikaUSAInc location is a subsidiary and is not treated as another Italian parent headquarters or issuer.
The company reports its latest integrated αDBS commercial release CE-marked in the European Economic Area in July2026; its September30,2026 announcement states the first ADVENT pivotal-study participant was implanted September21 in Monza. ADVENT NCT06891781 compares adaptive and conventional DBS in Parkinson’s disease; enrollment is under way, with104participants/up to18sites intended rather than already enrolled. U.S. use remains investigational under an FDA InvestigationalDeviceExemption, with no FDA commercial clearance or approval. Other named conditions on the site remain investigational/emerging applications.
Primary financing sources establish EUR1.7M first venture financing in2016, EUR8.4M SeriesA in2019, a separate EICAccelerator grant agreement with exact EUR2,499,999 EU contribution in2023, EUR2M additional EIC equity finance announcedJanuary22,2024 and EUR13.6M SeriesB announcedFebruary13,2025. An additional MichaelJFoxFoundation grant is corroborated but its amount and exact award day are unpublished. Grant commitments, project budgets, earlier selection dates and programme maxima are distinguished from actual disbursements or new equity. Current OrigineSGR is the exact same legal manager historically called InnogestSGR; historic Innogest participation is retained under that canonical manager, rather than creating a namesake investor. Other named buyers require full verified institutional profiles before linkage, and an undisclosed familyoffice is not invented as a company. | Cologno Monzese, Milan, Italy · Milan, Italy |
 Newstore | | |
 Newton Research | Newton Research operates in AI. | |
 Newton School | Company operating in Education. | |
 newtrul | newtrul operates in Logistics & Supply Chain. | |
 Newvoicemedia | | |
 NEX Health Intelligence | Develops an AI infection-intelligence platform for hospitals. It combines clinical, microbiology and patient-contact data to help infection-control teams identify possible cases, investigate transmission clusters and predict where infection risks may emerge. The software supports surveillance and targeted prevention workflows, with technology developed from research at Imperial College London. | |
 Nexa3D | | |
 Nexar | Mobility & Transportation company. | |
 Nexcade | Nexcade builds AI agents for freight forwarders, automating quotation, rate sourcing, tendering, bookings and related commercial workflows. Its agents combine information from emails, supplier portals, spreadsheets and transport-management systems, prepare work for review and carry shipment context between tasks. Freight teams control decisions while the software handles repetitive coordination and data entry. The company is based in London. | |
 NexDash | Berlin company developing an integrated, AI-operated electric freight network. NexDash acquires established trucking operators, electrifies their fleets and operates them using NexOS, its proprietary platform for route planning, energy and charging optimization, maintenance and fleet financing. It was founded in 2025 by Michael Cassau and originated from his Platform Horizons investment platform. Autonomous freight is a future development goal; electric fleet operations began in 2026. NexDash announced a EUR5 million seed round in November 2025, led by Extantia Capital with Clean Energy Ventures and Magnetic Capital participating. EIT Urban Mobility announced a EUR2.5 million pre-Series A investment commitment in June 2026; this is recorded separately from completed seed financing. | Berlin, Germany |
 Nexenta | Company operating in Infrastructure & Cloud. | |
 NexHealth | Founded in 2017, NexHealth streamlines the patient journey—from booking to intake, reminders, and payments—by syncing directly with practice EHRs. The company also provides a universal EHR API, enabling developers to build healthcare apps that integrate across dozens of systems. | 🇺🇸 · USA |
 Nexkey | Company operating in PropTech. | |
 Nexos | An enterprise AI orchestration platform for connecting, governing and managing multiple AI models and workloads. | |
 Nexos.ai | AI company. | |
 Nexprt | A cross-border B2B commerce platform connecting Indian manufacturers with global buyers, particularly in design-led home and décor categories. | |
 Next Caller | | |
 Next Matter | SaaS company. | |
 Next Practices Group | The Next Practices Group (NPG) is a US corporate holding network founded in2020 to support founder-led communications, marketing, public-affairs, security and technology businesses. Its own2023 announcement describes capabilities in software, data science, analytics and artificial intelligence. Its AI relevance also includes a documented corporate investment in Autonomize AI’s May2023 healthcare-AI seed financing. Founder Bob Pearson’s July2020 announcement separately identifies a significant minority investment in FosterEquity Services. This profile represents the historical NPG corporate buyer, with The Next Practice agency, its client relationships and independent venture managers distinguished. Ownership has evolved: The Next Practice agency announced joining Attivo inMay2025; NSG announced its January9,2026 management purchase of majority ownership from NPG, with NPG retaining a minority interest; and Highwire acquired The Bliss Group inJanuary2026. Neither those agency transactions nor group revenues establish an NPG venture fund or company fundraising round. Both historical published NPG domains were unavailable on review, so a complete current central team and present legal registration are unverified. Leadership roles are individually qualified to their latest primary confirmation; subsidiaries’ current employees are not presented as current NPG staff. | Austin, Texas, United States |
 NEXT Trucking | | |
 NextBillion.ai | | |
 nextbit | nextbit operates in Infrastructure & Cloud. | |
 Nextdoor | Nextdoor operates in Social & Community. | |
 Nexthop | | |
 Nexthop AI | Custom Ethernet and AI-cluster networking hardware and software, co-developed with hyperscalers. Founded in 2024 by former Arista COO Anshul Sadana. Headquartered in Santa Clara, California. | Santa Clara, California |
 NextInput | Company operating in Hardware & Semiconductors. | |
 NextPay | | |
 NexTravel | | |
 NextRoll | Company operating in Marketing & Advertising. | |
 NextSilicon | Company operating in Hardware & Semiconductors. | |
 NextVivo | | |
 NextVivo | | |
 Nexu | Nexu operates in Consumer. | |
 Nexus | Stanford-origin zkVM for verifiable computing, written in Rust. | San Francisco, California |
 Nexus | | |
 Nexus Enterprise | Infrastructure & Cloud company. | |
 Nexus Laboratories, Inc. | | |
 NexusAM | Develops AI software for real-time monitoring and qualification of metal additive manufacturing. It analyses sensor data during printing to identify defects, create traceable quality records and reduce the time and cost of certifying complex components for aerospace, medical and energy applications. | |
 Neysa | Company operating in AI. | |
 nFlux | nFlux develops AI and computer-vision software for manufacturing operations. Its systems guide workers through manual processes, detect errors on production lines and provide insights into product quality and efficiency. | |
 Nfon | Telecom company. | |
 Ngrok | API-first ingress-as-a-service. Founded 2015. San Francisco. | San Francisco, California |
 ngrow.ai | | |
 Niahealth | Company operating in Healthcare. | |
 Niantic | Location-based AR games including Pokémon Go. Spun out of Google 2015. | San Francisco, California |
 Niantic Labs | Consumer company. | |
 Niantic Spatial | Gaming company. | |
 Niantic, Inc. | | |
 Nibble Health | | |
 Nicira | A pioneer of software-defined networking and network virtualization whose technology became foundational to VMware NSX after its 2012 acquisition. | |
 Nicira Networks | A pioneer of software-defined networking and network virtualization, acquired by VMware in 2012 and integrated into the VMware NSX platform. | |
 Nifty Games | Nifty Games operates in Gaming. | |
 Night | Dallas creator talent management and media company. Raised $70M in Feb 2026 with Founders Fund among participants. Distinct from Night Media as a co-investor listing. | Dallas, Texas |
 Nightfall | Company operating in Cybersecurity. | |
 Nightfall AI | An AI-native data security and data loss prevention platform for discovering, classifying and protecting sensitive information. | |
 Nijta | Cybersecurity company. | |
 Niko | Niko operates in Climate & Energy. | |
 Nile | Nile operates in Infrastructure & Cloud. | |
 NILO | Gaming company. | |
 Nilo Health | Company operating in Healthcare. | |
 NILO Therapeutics | Biotech & Life Sciences company. | |
 Nilus | Nilus operates in Fintech. | |
 Nima | Company operating in Gaming. | |
 Nimbbl | India payments company. | India |
 Nimble Storage | A developer of predictive all-flash and hybrid storage systems that went public and was acquired by Hewlett Packard Enterprise in 2017. | |
 Nimbus | Electric vehicle startup founded in 2018 in Ann Arbor, Michigan, developing compact urban vehicles. A member of Y Combinator's Winter 2020 batch; YC currently lists the company as inactive. Distinct from the computational biotechnology company Nimbus Therapeutics. | |
 Nimbus Health | Nimbus Health operates in Healthcare. | |
 Nimbus Therapeutics | Clinical-stage biotechnology company using computational chemistry, structure-based design and machine learning to discover and develop investigational small molecule medicines. Its programs target cancer, immunological and metabolic diseases. Founded as Nimbus Discovery in 2009 and renamed Nimbus Therapeutics in 2015; headquartered in Boston. | |
 Nimsoft | | |
 Nine Fives | | |
 Ninebot | | |
 Nines | | |
 Ninjacart | Ninjacart operates in Food & Agriculture. | |
 NinjaOne | Company operating in Cybersecurity. | |
 NinjaTech AI | NinjaTech AI develops autonomous AI agents that help people research, write, code and complete digital tasks. Its SuperNinja assistant combines multiple AI models and tools to carry out work for individuals and businesses. | |
 Nino Foods | | |
 Niron Magnetics | Niron Magnetics develops and manufactures rare-earth-free permanent magnets using iron nitride, providing an alternative to magnets that depend on constrained critical-mineral supply chains. Its Clean Earth Magnet technology combines materials science and scalable manufacturing processes to serve electric motors and generators, industrial automation and robotics, vehicles, audio equipment, aerospace and defense, and datacenter infrastructure. The Minnesota company operates a commercial pilot plant and is building a full-scale magnet manufacturing facility in Sartell. | |
 Nirvana | | |
 Nirvana (Parallel) | Company operating in Fintech. | |
 Nirvana Health | Healthcare company. | |
 Nirvana Insurance | Insurance company. | |
 Nisonic | Nisonic is a Trondheim medical software company developing non-invasive assessment of intracranial pressure using ultrasound and machine learning. Its FAST-ICP software automatically analyses transorbital images of the optic nerve sheath, measures image-derived biomarkers and guides probe positioning. A SINTEF spin-out, it works with neurosurgeons and clinical researchers to validate these methods in patients with brain injuries and other neurological conditions. Its current FAST-ICP software is for research use, with clinical studies underway in Europe, Africa and the United States. | |
 Nitricity | Company operating in Food & Agriculture. | |
 Niva | Fintech company. | |
 Nivoda Limited | Company operating in E-Commerce & Marketplace. | |
 Niyo | | |
 Nlyte | Nlyte operates in Infrastructure & Cloud. | |
 NMD Pharma | NMD Pharma A/S is a Danish clinical-stage biotechnology company (CVR36899069), incorporated as an Aarhus University spin-out in2015, headquartered in Aarhus with US operations. It develops small-molecule therapies targeting skeletal-muscle chloride channel ClC-1 to improve neuromuscular transmission and muscle function. Its investigational lead ignaseclant, formerly NMD670, is being evaluated in Charcot-Marie-Tooth disease, generalized myasthenia gravis and spinal muscular atrophy. Additional research addresses age-related muscle weakness and sarcopenia. Its neuroscience relevance is neuromuscular biology and drug development; no unsupported claim that its platform is artificial intelligence is made.
The current primary website publishes seven management members, fifty-nine other team members, eight board members including the CEO, and three founding scientists. Functions not published in the general team directory remain qualified as Team Member; founding-scientist status is distinct from current executive employment. Current CMO Ana de Vera joined September2025, superseding older Jorge Quiroz CMO announcements. Current board affiliations are separately sourced and do not establish personal cash investments.
Actual primary funding includes a EUR2.7million seed investment in2016, a EUR38million SeriesA announced March23,2018, EUR35million financing announced February15,2022 (stage undisclosed in the issuer release), and EUR75million SeriesB announced November15,2023. A separate EUR629000 Innovation Fund Denmark grant was reported received November30,2020. The2014 EUR330000 pre-seed grant funded Aarhus University before incorporation and is not company financing. Historical2016–17 DKK44million cumulative support and later cumulative EUR155million or approximately USD180million statements are not separate new rounds. Closed company cash, grant awards, historical totals and currency renditions remain distinct. | Aarhus, Denmark · Boston, Massachusetts, United States |
 No Lean Season | An Evidence Action program that offered small, interest-free loans to help low-income rural Bangladeshi workers migrate temporarily for work during the lean season. | |
 Noah Labs | Berlin and Potsdam cardiovascular technology company developing AI-assisted remote monitoring and voice-based biomarkers for heart failure. Noah Labs Ark supports telemonitoring workflows, while Noah Labs Vox studies changes in speech as signals of cardiac decompensation. The company collaborates with clinical research centers to evaluate its technology. | |
 Noat | Discover NOAT: Swedish-made, premium nicotine pouches. Tobacco-free, long-lasting, and designed for a smoother experience. | |
 Nobell | Engineers soybeans to produce casein for animal-free cheese. Also known as Alpine Bio. | South San Francisco, California |
 Nobell Foods | Nobell Foods operates in Food & Agriculture. | South San Francisco, California |
 Nobell Foods | | |
 Nobl9 Inc. | Infrastructure & Cloud company. | Waltham, MA, US |
 Noble | Company operating in Fintech. | |
 NobodyWho | NobodyWho is a Copenhagen company developing an open-source AI inference engine that runs language models directly on phones, laptops and embedded devices, or on GPU servers controlled by an organisation. Its on-device and on-premises deployments keep prompts and outputs within the customer’s infrastructure and can work offline without per-token API fees. The EUPL-licensed engine supports compact and larger open models through developer SDKs. Its paid Assurance Layer provides deployment, model selection and optimisation, governance, monitoring, support and tools adapted to customer workflows. | |
 NOCD | NOCD Inc. is a Chicago-based digital behavioral healthcare company specializing in obsessive-compulsive disorder and related conditions. Its licensed therapists deliver live video exposure and response prevention therapy, supported between sessions by messaging, symptom and ERP tools, and a patient community in the NOCD app. The company’s proprietary Noto platform uses AI-enabled tools for clinical documentation, scheduling, case management and therapist development; this supports clinician-delivered care rather than establishing autonomous diagnosis or a medication product. Founder Stephen Smith began designing the idea in 2014, and the current company story identifies its mission as beginning in 2015. NOCD publishes clinical outcomes research and serves patients across the United States and internationally where licensed. In January 2026, its investor 7wire Ventures reported NOCD’s acquisition of PTSD-care company Rebound Health and launch of Noto as a new parent-company platform; the NOCD brand and NOCD Inc. remain identified on the current service site. | Chicago, Illinois, United States |
 Nocion Therapeutics | Company operating in Biotech & Life Sciences. | |
 NocoDB | Data & Analytics company. | |
 NODA AI | NODA AI operates in Defense & Space. | |
 Nodals AI | AI advertising-technology company providing a platform for media owners to plan and deliver campaigns against advertiser outcomes. | |
 Noded | Noded operates in SaaS. | |
 Nodes Links | Construction company. | |
 Nodeshift | Nodeshift operates in Infrastructure & Cloud. | |
 Noema Pharma | Noema Pharma AG is a Basel clinical-stage biotechnology company developing oral small-molecule therapeutics for neurological and related disorders. Sofinnova Partners seed-financed its formation in 2019, and the company licensed four clinical-stage assets from Roche. Its current pipeline focuses on two programs: basimglurant (NOE-101), an mGluR5 negative allosteric modulator for trigeminal neuralgia, and cendifensine (NOE-115), a broad-spectrum monoamine modulator for menopause-related vasomotor and other symptoms. The website labels basimglurant Phase 2/3 and reports an FDA Fast Track designation; the candidates remain investigational. Earlier announcements described additional studies in tuberous sclerosis complex, Tourette syndrome and childhood-onset fluency disorder, which are retained as historical development context rather than assumed to remain the current pipeline. Noema’s public directory contains six executives, nine board seats and five scientific advisors, representing19 distinct people. Ilise Lombardo leads the company as CEO and director. Noema closed a CHF54M Series A in December2020 and a CHF103M Series B in March2023. Its December2024 extension brought the total Series B round to CHF130M; this is not a separate CHF130M cash raise. The independent Swiss Venture Capital Report2025 directly reports CHF27M for the2024 extension; the issuer itself published the CHF130M aggregate rather than a separate incremental amount. The2019 seed amount remains undisclosed. Roche’s original shareholding was consideration for licensed assets, distinct from a proved cash investment. | Basel, Switzerland |
 Noetica | AI benchmarking of corporate debt documents. Founded 2022. New York. | New York, New York |
 Noetik | Develops AI models of human tumor biology to discover and develop precision cancer therapies. It combines spatial imaging and other molecular data from human tumors with machine learning to model tumor microenvironments, identify therapeutic targets and predict which patients may respond to treatments. | |
 Nofence | Company operating in Food & Agriculture. | |
 Nohla Therapeutics | | |
 Nolea Health | | |
 Nolla Health | Healthcare company. | |
 Noloco | | |
 Nomad Homes | Company operating in PropTech. | |
 Nomadic | Nomadic develops AI video understanding tools that turn autonomous vehicle and robotics footage into searchable, structured datasets for training and evaluating physical AI systems. | |
 Nomagic | Company operating in Robotics & Automation. | |
 Nomba | Company operating in Fintech. | |
 Nomi | Nomi operates in AI. | |
 Nomic Bio | Nomic Bio develops and operates a quantitative protein-profiling platform for pharmaceutical, biotechnology and academic researchers. Its nELISA technology miniaturizes sandwich immunoassays onto color-coded beads and uses DNA-programmable linkers to isolate antibody pairs, reducing cross-reactivity while measuring many proteins across large sample sets. The company provides an end-to-end profiling service, including sample processing, quality control and data delivery, with an Omni 1000 broad protein panel, application-focused Core panels and configurable Flex panels. Its Portal supports analysis and organization of study data. Researchers use these measurements for drug discovery, biomarker development and translational studies; Nomic operates in Montreal and the Boston area. | |
 Nomiku | | |
 Nominal | Data platform for hardware engineering teams to review test data and validate critical systems. Founded in 2022. Offices in Los Angeles, Austin, and New York. | Los Angeles, California · Austin, Texas |
 Nominum | | |
 Nomio | Intelligent contract database | UK |
 Nomis | | |
 Nomis Solutions | | |
 Nomod | Merchant payments. | |
 Nomos | | |
 Noname | | |
 Noname Security | | |
 Nonstop Games | | |
 Noom | Noom operates in Healthcare. | |
 Noon | | |
 Noon Home | Company operating in PropTech. | |
 Noora Health | | |
 Nopan | Fintech company. | |
 NORBr | Company operating in Fintech. | |
 Nord Security | Cybersecurity company. | |
 Nordsense | Company operating in Infrastructure & Cloud. | |
 NoRedInk | Education company. | |
 Norlase | Norlase ApS is a Danish ophthalmic medical-device company (CVR/VAT35644547) commercializing laser technology developed at the Technical University of Denmark. It develops compact laser photocoagulation systems for retinal disease and glaucoma. Its LEAF, LION, ECHO and LYNX products combine semiconductor-laser technology with portable, fiberless designs, pattern scanning, wireless interfaces and voice control. The company operates in Ballerup, Denmark and Redwood City, California. Its relevance is deep technology, photonics and vision-related medical devices; voice control is a published feature, while an AI drug-discovery or neural-implant platform is not claimed.
The live management page publishes eight named leaders and their authentic captioned portraits. Board releases document co-founder Jacob Philipsen becoming chair in February2025, succeeding co-founder David Hardwick, who remained a board member. Maya Barley’s board appointment was announced July2024. These board affiliations are qualified to the latest source dates where a complete current board index is unpublished.
Primary sources verify an additional USD4.1million equity raise during2020 through West Hill Capital, USD10.6million SeriesB announced October25,2021, and USD11million financing announced in the body of the May23,2023 release. West Hill organizes investor syndicates; these links do not assert its LLP treasury supplied every dollar. The European Investment Bank project register records a EUR20million venture-debt facility signed December20,2024, announced February27,2025; capacity is distinguished from unknown actual drawdowns. Spring Nordic’s own portfolio verifies an undated investment relationship with no inferred priced round.
CORDIS verifies three separate Horizon2020 grant agreements: CoDiS672196, CoDiS734075 and MILAS739714. Their Norlase net contributions are EUR50000, EUR1180012.05 and EUR114780 respectively. CoDiS734075 total project EU contribution EUR1423043.30 includes other beneficiary allocations and is not wholly Norlase cash. Grant agreements, project cost, paid cash, secondary share transactions and cumulative fundraising totals remain distinct. Other older national/programme awards and secondary ownership are retained in the research queue until precise beneficiary, institution and event evidence is established. | Ballerup, Denmark · Redwood City, California, United States |
 Norm Ai | Norm Ai operates in Legal. | |
 Normal Computing | Applied AI and semiconductor company developing AI software for chip design and thermodynamic computing hardware that uses stochastic physics for generative AI workloads. | |
 Normalyze | | |
 Normalyze, Inc. | | |
 Norstel | A Swedish manufacturer of silicon-carbide wafers for power-semiconductor applications, fully acquired by STMicroelectronics in 2019. | |
 Nortech AI | AI company. | |
 North | | |
 Northflank | Company operating in Developer Tools. | |
 NorthLadder | Operates a trade-in and resale platform for used electronics, connecting brands and retailers with business buyers. | |
 Northwood | Satellite ground-station network. Series A with Founders Fund. CEO Bridgit Mendler. | El Segundo, California |
 Northwood Space | Satellite ground-station network. Series A with Founders Fund. CEO Bridgit Mendler. | El Segundo, California |
 Nory | Nory operates in SaaS. | |
 Nostics | Develops diagnostic technology using nanotechnology to identify pathogens in patient samples. | |
 Nostos | Biotech & Life Sciences company. | |
 Nostos Genomics | Biotech & Life Sciences company. | |
 Notabene | | |
 Notabene Id | | |
 Notable | Notable operates in Healthcare. | |
 Notable Labs | Biotech & Life Sciences company. | |
 Notch | Automated customer support system powered by generative AI across text-based channels in almost all languages. Later described as an AI OS for regulated industries. | Tel Aviv, Israel |
 Notch | | |
 Notch.cx | | |
 Noteable | Company operating in Healthcare. | |
 Notebook Labs | | |
 Notion | Provides a collaborative workspace for documents, knowledge bases and project tracking, with AI-assisted search and content tools. | |
 Notte Labs, Inc | | |
 Nourish | Nourish operates in Healthcare. | |